These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 667827)

  • 21. [Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].
    Kudriavtsev IA; Paramonova TD; Golenko OD; Miasishcheva NV
    Probl Gematol Pereliv Krovi; 1982 Jul; 27(7):27-31. PubMed ID: 7122454
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined interferon--antimetabolite therapy of murine L1210 leukemia.
    Slater LM; Wetzel MW; Cesario T
    Cancer; 1981 Jul; 48(1):5-9. PubMed ID: 6165457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
    Neil GL; Homan ER
    Cancer Res; 1973 Apr; 33(4):895-901. PubMed ID: 4696483
    [No Abstract]   [Full Text] [Related]  

  • 25. Rationale of chemotherapeutic adjuvant treatment.
    Goldin A
    Arch Geschwulstforsch; 1978; 48(7):627-35. PubMed ID: 736743
    [No Abstract]   [Full Text] [Related]  

  • 26. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
    Semon JH; Grindey GB
    Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
    [No Abstract]   [Full Text] [Related]  

  • 27. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synchronization of L1210 leukemia with hydroxyurea infusion and the effect of subsequent pulse dose chemotherapy.
    Moran RE; Straus MJ
    Cancer Treat Rep; 1980 Jan; 64(1):81-6. PubMed ID: 7379059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE; Burns ER; Halberg F; Pauly JE
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in sustained release of antineoplastic drugs using liposomes which avoid uptake into the reticuloendothelial system.
    Allen TM; Mehra T
    Proc West Pharmacol Soc; 1989; 32():111-4. PubMed ID: 2780575
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
    Valeriote F; Vietti T; Coulter D
    J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effectiveness of combined action of vitamins A, E and C and cyclophosphane or adriamycin on growth of transplanted tumors in mice].
    Mosienko VS; Khasanova LT; Sukolinskiĭ VN; Morozkina TS
    Eksp Onkol; 1990; 12(3):55-7. PubMed ID: 2344827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin.
    Edelstein M; Vietti T; Valeriote F
    Cancer Res; 1974 Feb; 34(2):293-7. PubMed ID: 4810905
    [No Abstract]   [Full Text] [Related]  

  • 34. Vitamin A: failure to demonstrate in mice an anti-tumour effect, whether combined with cytotoxic drugs or not.
    Cattan A; Bresson ML
    Bull Cancer; 1986; 73(2):201-6. PubMed ID: 3730637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined therapy of L1210 leukemia with Damvar and cytostatics.
    Pujman V; Cernochová S
    Neoplasma; 1979; 26(5):521-3. PubMed ID: 522924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of advanced breast cancer with 2 successive chemotherapeutic schedules].
    Pérez JE; Machiavelli M; Romero A; Leone BA; Rabinovich MG; Arévalo E
    Medicina (B Aires); 1982; 42(6 Pt 1):587-95. PubMed ID: 6897849
    [No Abstract]   [Full Text] [Related]  

  • 38. Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ; Otter GM; Stock CC
    Cancer Treat Rep; 1976 Jan; 60(1):23-7. PubMed ID: 1000516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I; Venditti JM; Tyrer DD; Goldin A
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract]   [Full Text] [Related]  

  • 40. Combined therapy of L1210 leukemia with cyclophosphamide and lycurim.
    Stoychkov JN; Milushev AS; Todorov DK
    Neoplasma; 1980; 27(1):33-6. PubMed ID: 6892839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.